Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
10 business days till take off !!!! ARE youuuuuuuuu Ready :)
BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone, Ph.D
By GlobeNewswire, January 05, 2018, 11:40:00 AM EDT
Vote upAAA
ANAHEIM, CA, Jan. 05, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has retained regulatory drug experts Priya Jambhekar and Bruce Firestone, PhD, to assist with the drug development and regulatory process for BioCorRx's product pipeline. Ms. Jambhekar and Dr. Firestone are additions to the Company's current team, which is preparing for its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) scheduled on January 24, 2018. As previously announced, the Company is seeking FDA approval for BICX102, a naltrexone implant for the treatment of opioid and alcohol use disorders.
Ms. Jambhekar is a drug development entrepreneur with over 25 years of executive experience in worldwide regulatory, quality, clinical and pharmacovigilance operations, as well as early and late stage development product registration and commercial support. She has held positions including Global Senior Vice President of Regulatory & Quality Operations at Paramount BioSciences, Global Vice President at Ethicon, a Johnson & Johnson company, and Worldwide Vice President of Regulatory and Government Relations at Alkermes. Other senior positions include Baxter ACC, as Regulatory Head of Compliance, and Bristol-Myers Squibb, as Manager of Regulatory, Safety, Compliance. She is also certified by the Regulatory Affairs Professional Society and the New Jersey Pharmaceutical Quality Control and Assurance Society.
Dr. Firestone has over three decades of pharmaceutical research & development experience with on-time delivery of over 15 product approvals as new chemical entities and line extensions. Dr. Firestone is an accomplished author with over 40 publications, abstracts and patents. He also has extensive chemistry, manufacturing and controls (CMC) expertise with: small molecules, drug and drug-device combinations, sustained-release products, semisolids, topical and intravitreal routes of administration. He has held senior positions at Allergan and is an expert in pharmaceutical product development, manufacturing process development and scale-up, technology transfer, process validation, risk management, technology assessment, due diligence, CMC documentation, and CMC strategy.
Brady Granier, President, CEO and Director, stated, "Priya and Bruce are valuable additions to the BioCorRx team and we are honored to have them on board. They both bring extensive regulatory and manufacturing experience in drug development and have proven track records bringing drugs to market. We look forward to their contributions as we accelerate our efforts to obtain FDA approval for our naltrexone product that we feel will help many families suffering from the current opioid epidemic and massive alcohol dependence problem."
About BioCorRx
BioCorRx Inc. (OTCQB:BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
nrudman@crescendo-ir.com
Source: BioCorRx Inc
Developments in the Biotech and Pain Management Therapeutics Segments
9:00 AM ET 1/5/18 | Dow Jones
FinancialBuzz.com News Commentary
NEW YORK, January 5, 2018 /PRNewswire/ --
According to a report by Grand View Research, Inc. the global biotechnology market is expected to reach USD 727.1 billion by 2025. Major technological advancements in segments such as regenerative medicine and genetics in diagnostics are important drives for the future of biotechnology. Innovative companies in the industry are engaged in large clinical trials and strong R&D investments for cancer therapeutics, as oncology is one of the most promising areas of focus in the biotech industry. Another large segment of the market is pain management therapeutics. Transparency Market Research indicates that the global market for pain management therapeutics has a high degree of competition, and is witnessing a continual entry of new companies owing to the high growth prospects. In terms of type of therapeutics, opioids and NSAIDS are the leading segments that account for key shares in the pain management therapeutics market. BioCorRx Inc. (OTC: BICX), Curis, Inc. (NASDAQ: CRIS), DURECT Corporation (NASDAQ: DRRX), Egalet Corporation (NASDAQ: EGLT), Trevena, Inc. (NASDAQ: TRVN).
Opioids are the most widely prescribed medications or the treatment of chronic pain conditions. A report by Transparency Market Research explains that these analgesics are used to manage pain in cancer patients and also to treat severe constant pain in patients suffering from terminal illnesses. Opioids are also a major cause of drug overdoses. The New York Times reported data provided by the CDC, according to which Drug overdoses killed roughly 64,000 people in the United States in 2016. A very strong increase of more than 22 percent from the previous year. According to the Times, "Drug overdoses are expected to remain the leading cause of death for Americans under 50, as synthetic opioids - primarily fentanyl and its analogues - continue to push the death count higher."
BioCorRx Inc. (OTCQB: BICX) recently announced breaking news that the Company's BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, was featured on CBC affiliate WBNS-10TV news in Ohio. The program features an individual suffering from opioid use disorder who has turned his life around since starting the BioCorRx Recovery Program. Participation in the Company's program was accepted in lieu of conviction by a Richland County judge in Ohio.
A link to the news story is available at: https://www.10tv.com/article/hi-tech-treatment-now-possible-opiate-addiction. After the segment aired, an update of the cost for treatment was posted in the written article associated with the video. The cost mentioned is the national average for the entire outpatient program that varies by each independent location and also typically includes medical follow-ups, cognitive behavioral therapy (CBT) with a licensed therapist for approximately 3 months and an overlapping peer recovery support and patient outcome tracking for one full year. In some cases, it may even include outpatient detox.
Brady Granier, CEO, President, and Director of BioCorRx, commented, "It's great to see our program featured in Ohio, one of the states most devastated by the opioid epidemic. More importantly, it's emotionally rewarding to see people get on their journey to recovery with our program. We are also honored that our program was approved to be utilized as treatment in lieu of conviction. We hope to see more of this in the future as it can help people get well and on the road to recovery, while also reducing the financial burden of incarceration on society."
About BioCorRx - is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit http://www.BioCorRx.com. "
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge(R) for the treatment of advanced basal cell carcinoma. On November 7, 2017, the company reported its financial results for the third quarter ended September 30, 2017. Revenues for the third quarter of 2017 were $2.4 million, as compared to $1.8 million for the same period in 2016. Revenues for the nine months ended September 30, 2017 were $6.6 million, as compared to $5.2 million for the same period in 2016. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge(R).
DURECT Corporation (NASDAQ: DRRX) is a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DURECT's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR(R) (SABER(R)-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery. On December 13, 2017, the company announced that Indivior PLC has reported that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for RBP-7000. RBP-7000 is an investigational, once-monthly injectable risperidone for the treatment of schizophrenia. Indivior PLC further reported that the FDA has set a PDUFA (Prescription Drug User Fee Act) target action date of July 28, 2018.
Egalet Corporation (NASDAQ: EGLT), a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Using Guardian Technology, Egalet is developing a pipeline of clinical-stage, product candidates for which we are seeking partners including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Recently, the company announced that it has partnered with OraPharma, Inc., a division of Valeant Pharmaceuticals International, Inc., to co-promote SPRIX (ketorolac tromethamine) Nasal Spray to dentists, dental specialists and oral surgeons across the United States. SPRIX Nasal Spray is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term (up to five days in adults) management of moderate to moderately severe pain that requires analgesia at the opioid level.
Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. Recently, the company announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for OLINVO(TM) (oliceridine) Injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018. OLINVO is an investigational product for the management of moderate to severe acute pain. It is the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer associated adverse effects.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
(MORE TO FOLLOW) Dow Jones Newswires
January 05, 2018 09:00 ET (14:00 GMT)
Developments in the Biotech and Pain Management -2-
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has not been compensated. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news dissemination and PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com.
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
URL: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
> Dow Jones Newswires
January 05, 2018 09:00 ET (14:00 GMT)
Any positive news will take us there in a heart beat !
Another 100k trade
That thing is set to explode any day !
Insider Financial
Biocorrx Inc (OTCMKTS:BICX) BIOTECH
Biocorrx Inc (OTCMKTS:BICX) Is An Opioid Crisis Play
ByJarrod WessonPosted on January 3, 2018
Are you aware of the dramatic opioid epidemic in the United States? It is devastating for the country. Many have already said that it is one of the most significant problems in the country. President Trump, for instance, said recently that it is a national public health emergency.
We identified this dramatic situation and looked for several companies providing treatment for substance abuse addiction. We believe that they do not only bring an opportunity to help people. Instead, they represent a significant market opportunity because the amount of treatments demanded is growing and increasing the revenues of addiction treatment companies.
One of the most exciting business profiles operating in this sector is Biocorrx Inc. (OTCMKTS:BICX), which was founded in 2008 and is headquartered in Anaheim, California. It was featured by us nine months ago in an article, in which many useful facts were pointed out. First of all, the most interesting was the positive preliminary data from preclinical studies evaluating BICX101; the company’s product. Additionally, we appreciated that the Fox Channel had also featured the company, which, we believe, should have increased awareness.
Is there any new information?
Yes, firstly, judging by the bull action in BICX’s stock price, it’s time to take a closer look at Biocorrx Inc. Have a look at it:
One month stock chart for Biocorrx Inc OTCMKTS:BICX
1-month chart for BICX
But, there is more to be noted. The most significant is the submission of pre-Investigational New Drug package to the U.S. Food and Drug Administration for the BICX102. Also, new agreements with several organizations, such as the National Institute on Alcohol Abuse and Alcoholism, and several distribution contracts seem to be making the share price pop up. We will tell you everything that you need to know in this new update.
Recent Developments
In December 2017, we could see how BICX’s share price increase violently as a result of much good news regarding the company. But, the truth is that the market has been receiving intelligence noting company’s growth for the last 6 months. Let us provide the most significant press releases.
On September 12, 2017, it released the completion and beta launch of the company’s proprietary mobile application for use by licensed behavioral specialists and individuals in treatment for opioid and alcohol use disorders. It was ready in the Apple App Store and Google Play on September 21, 2017. BICX had collaborated with DynamiCare Health™, Inc. in designing this new tool, which helps counselors and therapists remotely monitor the progress of their patients as they complete the BioCorRx CBT program. It is a great business innovation that should increase the revenues because the number of patients will improve.
On October 5, 2017, a new business line was announced. BICX had decided to commence a pilot program for weight-loss with Atlantis Medical Wellness & Weight Loss Center in Silver Spring, MD. The idea is quite ambitious and smart, as the market in which the company will be entering is large. According to the CDC, more than one-third (36.5%) of U.S. adults have obesity and the estimates of current healthcare costs of obesity range from $147 billion to nearly $210 billion per year. This news noted again that the company is looking for expanding its products, which, we believe, will help the business grow in the new year 2018.
On October 25, 2017, the company noted that Advanced Spine and Pain would implement the BioCorRx® Recovery Program in all nine locations in the Maryland and Virginia area. It was not said when the revenues from this new client would be shown to the market, but we encourage readers to be very alert. In the next quarter, the top of the P&L could increase as a result of this new agreement. Only those who were able to read this news will be able to know why.
It seems that the treatment offered by BICX commenced becoming well-known in the sector by the end of 2017. We made this impression after the company released a confidentiality agreement with the National Institute on Drug Abuse. It was big news, as this is the United States federal-government research institute; in charge of “advancing science on the causes and consequences of drug use and addiction.” Also, it was noted that NIDA agreed to participate as an observer at the pre-IND meeting for BICX102 with the FDA, which is scheduled for January 24, 2018.
Regarding the relations with the FDA, be sure to follow the company in January 2017. Everything seems to be ready for these meetings after the company released in December that it had submitted its pre-Investigational New Drug package to the U.S. Food and Drug Administration for the Company’s naltrexone implant, BICX102. In the following weeks, we will get to know some conclusions from the FDA regarding the commercialization of BICX102. It could push the share price higher.
The Government of the US was not the only institution interested in BICX102 in 2017. CereCare, LLC, for instance, also announced that it would become a partner of BICX. This company will be investing $100,000 and receive restricted shares in BioCorRx plus performance-based options for reaching certain milestones. CereCare will have exclusive distributorship rights for the BioCorRx Program in Nevada, subject to specific performance criteria. This company, which operates medical clinics under its CereCare in Los Angeles, Sherman Oaks, California and Reno, Nevada, seems to believe that the new treatment will be successful. They will be financing some of the company’s expenses and will be able to profit from the distribution rights.
What did finally make the share price increase?
The previous news did not seem to excite the market, as the share price did not move much. We believe that the share price did not spike until the BioCorRx® Recovery Program was featured on CBC affiliate WBNS-10TV news in Ohio.
The most interesting note in the news was that the treatment was accepted instead of conviction by a Richland County judge in Ohio. In our opinion, if other judges in other States commence allowing the treatment, it will push up the revenue line. Be sure to look for this type of news from the company.
Conclusion
Currently trading with a market cap of $40 million, BICX is an exciting story among small caps. The company shows $0.28 million in cash, $0.6 million in total assets, and $3.2 million in total liabilities. Additionally, the company made $0.7 million in total revenues in 2016 and reported $0.14 million in revenues for the quarter ended September 30, 2017. We believe that with the growth recently shown, it will not be difficult to refinance the balance sheet to sustain future growth. Other companies, like CereCare, LLC, may be interested in doing so.
Be sure to check out our coverage on BICX!
We will be updating our subscribers as soon as we know more. For the latest updates on BICX, sign up below!
Disclosure: We have no position in BICX and have not been compensated for this article.
A 100k just went through as a single trade @ 0.172
BIG CHANCE will Break the 0.20s today any time during the day :)may be even touch the 0.25 .....
Been here for years seen that BICX trading trend several times :)
Get ready !!!! Go BICX ......
BioCorRx CEO, Brady Granier, Appears on Fox
Font size: A | A | A
7:30 AM ET 1/2/18 | GlobeNewswire
BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic
ANAHEIM, CA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as a guest on Fox & Friends to discuss the BioCorRx(R) Recovery Program and the naltrexone implant for the treatment of opioid use disorder. The segment can be viewed online at: https://www.biocorrx.com/news-media/media.
Fox & Friends is a daily morning news/talk program airing on Fox News Channel. It begins at 6:00 a.m. Eastern Time with the latest Fox News Live headlines and news of the morning and continues with a variety of segments including current events, interviews, updates of news stories with correspondents, political analysis from the hosts, and entertainment segments.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
> Dow Jones Newswires
January 02, 2018 07:30 ET (12:30 GMT)
I can clearly say that 2018 specially Jan 2018 will be an awesome month for BICX !! 0.50+ easy
We might break the 0.12 resistance today if it kept trading the same way till close .
VERY good point !!
BioCorRx Recovery Program Used in Lieu of Conviction in Ohio
Font size: A | A | A
9:41 AM ET 12/22/17 | GlobeNewswire
BioCorRx Recovery Program Used in Lieu of Conviction in Ohio
ANAHEIM, CA, Dec. 22, 2017 (GLOBE NEWSWIRE) --
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that that the Company's BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, was featured on CBC affiliate WBNS-10TV news in Ohio. The program features an individual suffering from opioid use disorder who has turned his life around since starting the BioCorRx Recovery Program. Participation in the Company's program was accepted in lieu of conviction by a Richland County judge in Ohio.
A link to the news story is available at: https://www.10tv.com/article/hi-tech-treatment-now-possible-opiate-addiction. After the segment aired, an update of the cost for treatment was posted in the written article associated with the video. The cost mentioned is the national average for the entire outpatient program that varies by each independent location and also typically includes medical follow-ups, cognitive behavioral therapy (CBT) with a licensed therapist for approximately 3 months and an overlapping peer recovery support and patient outcome tracking for one full year. In some cases, it may even include outpatient detox.
Brady Granier, CEO, President, and Director of BioCorRx, commented, "It's great to see our program featured in Ohio, one of the states most devastated by the opioid epidemic. More importantly, it's emotionally rewarding to see people get on their journey to recovery with our program. We are also honored that our program was approved to be utilized as treatment in lieu of conviction. We hope to see more of this in the future as it can help people get well and on the road to recovery, while also reducing the financial burden of incarceration on society."
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
nrudman@crescendo-ir.com
> Dow Jones Newswires
December 22, 2017 09:41 ET (14:41 GMT)
0.105
here we goooooooo !!!! 0.10 got hit
Big possibility
BID climbing 0.093 ... we are moving ??
ASK 0.099 !! GO BICX
0.092 !!!!!
Now !!!! VERY POSITIVE NEWS :)
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
7:30 AM ET 12/19/17 | GlobeNewswire
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
ANAHEIM, CA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has submitted its pre-Investigational New Drug (pre-IND) package to the U.S. Food and Drug Administration (FDA) for the Company's naltrexone implant, BICX102. BICX102 is the Company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.
The submitted pre-IND package provides the FDA with current information on BICX102, as well as the proposed development plan. The purpose of the meeting is to review the development plan and to seek the agency's guidance on further development and commercialization of BICX102.
This pre-IND submission follows BioCorRx's recent announcement that the FDA has granted the Company a Type-B pre-IND meeting scheduled for January 24, 2018. As previously announced, the National Institute on Drug Abuse (NIDA) has agreed to attend the pre-IND meeting for BICX102 with the FDA. NIDA and National Institute on Alcohol Abuse and Alcoholism (NIAAA) have also received the documents which were submitted to the FDA.
Brady Granier, CEO, President, and Director of BioCorRx, commented, "We are pleased that BioCorRx(R) will be starting out the New Year with a meeting with the FDA. The submission of the pre-IND package is a major step that BioCorRx(R) has completed in its efforts to bring BICX102 to market. We thank all of our advisors and consultants for their tireless efforts in putting together a package that we feel will lead to a very productive meeting. We are pursuing the 505(b)(2) regulatory pathway, which we believe will be a more rapid and cost-effective route to approval. We are pleased that both NIDA and NIAAA are involved in this process and we look forward to the meeting with the FDA."
About BioCorRx(R)
BioCorRx(R) Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx(R) Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx(R) Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
> Dow Jones Newswires
December 19, 2017 07:30 ET (12:30 GMT)
Up we gooooooo !!
Little action before year end !!!!!!
BioCorRx Provides Business Update for the Third Quarter of 2017
Nov 16, 2017 08:00:00 (ET)
BioCorRx Provides Business Update for the Third Quarter of 2017
Investor Call to be held on Friday, November 17th at 2:00 PM ET
ANAHEIM, CA--(Marketwired - Nov 16, 2017) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2017.
Key operational highlights include:
-- Pre-IND meeting for BICX102 with the U.S. Food & Drug Administration on
track for January 24, 2018
-- Entered into a confidentiality agreement with the National Institute on
Drug Abuse (NIDA)
-- BioCorRx(R) pilot program for weight-loss underway
-- DynamiCare Rewards(TM) mobile app now available to doctors, as well as
local, state, and federal government entities
Brady Granier, President, CEO and Director, stated, "We continue to add more clinics that offer our BioCorRx(R) Recovery Program. Last month, we announced that Advanced Spine and Pain (ASAP) will implement the BioCorRx(R) Recovery Program in all nine of its locations in the Maryland and Virginia area. ASAP is the latest group of centers to implement the BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program. The program combines the use of a patient specific naltrexone implant with a proprietary cognitive behavioral therapy (CBT) program specifically tailored for the treatment of alcohol and opioid use disorders, along with one year of peer recovery support and tracking. We continue to see interest for our treatment program which is now available in about a dozen states from independent treatment providers and we believe we are well positioned to continue that nationwide expansion.
"At the end of September, we announced an update on commercialization efforts for the Company's naltrexone implant, BICX102. We requested a pre-IND meeting for BICX102 with the U.S. Food & Drug Administration (FDA), which has been scheduled for January 24, 2018. We continue to work with Innovative Science Solutions (ISS) and Dr. Bal Brar on the briefing package preparation which is required to be submitted 4 weeks prior to the meeting. We are pleased with the progress of the documents and look forward to presenting them to the FDA.
"Yesterday, we announced that we entered into a confidentiality agreement with the National Institute on Drug Abuse (NIDA), a United States federal-government research institute. The purpose of the agreement is to share confidential information and potentially collaborate on further research, development and commercialization of our therapies and programs for opioid use disorder. NIDA also agreed to participate as an observer at the pre-IND meeting for BICX102 with the FDA. We are pleased with their interest in this project and I look forward to meeting with them next week.
"In September, we announced the completion and beta launch of our proprietary mobile application for use by licensed behavioral specialists and individuals for the treatment of patients with opioid and alcohol use disorders. The mobile application, DynamiCare Rewards(TM) with BioCorRx(R) CBT, is designed to offer patients a self-guided interactive version of BioCorRx's proprietary, naltrexone specific, CBT program under the supervision of licensed professionals. The new platform will enable counselors and therapists to remotely monitor the progress of their patients as they complete the proprietary program modules. The BioCorRx(R) CBT program consists of 35 modules developed by addiction experts with years of experience treating individuals receiving long-term naltrexone therapy. We have received significant interest from state and federal entities. Our plan is to offer our mobile application to independent doctors, as well as local, state, and federal government entities that are currently offering sustained release naltrexone programs, in order to increase patient compliance. We believe this app is a great value proposition while creating scalable new opportunities to monetize our platform, both domestically and abroad.
"In October, we announced that we began a pilot program for weight-loss with Dr. Benjamin Gonzalez, Medical Director of Atlantis Medical Wellness & Weight Loss Center in Silver Spring, MD. Naltrexone is a fascinating medication with many potential uses and we feel that it will have a positive impact on weight management by reducing food cravings. We also see the likelihood for it to prevent the potential for transferred addiction to other substances for post bariatric patients such as those who get gastric bypass surgery. The weight-loss program is being designed to help people lose weight and learn realistic ways to incorporate new healthy behaviors into their everyday lives. This is an exciting endeavor for our company and we look forward to the results of the pilot which is already underway."
Lourdes Felix, CFO, COO and Director, commented, "We continue to carefully manage our expenses and have maintained a low cash burn despite the fact we are moving forward aggressively with the regulatory process for our naltrexone implant, BICX102. Moreover, with the growth in new clinics that offer our BiCorRx(R) Recovery Program, we anticipate improved revenues in the fourth quarter, and even more so, as we head into 2018. Aside from the revenue potential of the BiCorRx(R) Recovery Program on a standalone basis, we believe future cash flow from this business will help fund our drug development initiatives."
Conference Call
BioCorRx will host a conference call on Friday, November 17th at 2:00 p.m. Eastern Time to discuss the company's financial results for the third quarter ended September 30, 2017, as well as the Company's corporate progress and other meaningful developments. If investors have any questions that they would like to pose to management, please email BICX@crescendo-ir.com before the conference call.
The call will be available on the Company's website at www.BioCorRx.com, or by calling 877-407-8031 for U.S. callers or +1 201-689-8031 for international callers.
A webcast will also be archived on the Company's website and a teleconference replay of the conference call will be available approximately one hour following the call, through midnight December 1, 2017, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 22790.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx(R) Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
BICX@crescendo-ir.com
212-671-1020 x304
(MORE TO FOLLOW) Dow Jones Newswires
November 16, 2017 08:00 ET (13:00 GMT)
BioCorRx Enters Confidentiality Agreement with Federal Government Research Institute; Plans to Attend FDA Meeting for Naltrexone Implant
Nov 15, 2017 07:30:00 (ET)
BioCorRx Enters Confidentiality Agreement with Federal Government Research Institute; Plans to Attend FDA Meeting for Naltrexone Implant
ANAHEIM, CA--(Marketwired - Nov 15, 2017) - BioCorRx, Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that it has entered into a confidentiality agreement with the National Institute on Drug Abuse (NIDA), a United States federal-government research institute whose mission is "to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health." The purpose of the agreement is to share confidential information and potentially collaborate on further research, development and commercialization of the Company's therapies and programs for opioid use disorder.
According to the 2016-2020 NIDA Strategic Plan, one of the goals is to "develop new and improved treatments to help people with substance use disorders achieve and maintain a meaningful and sustained recovery." More information about NIDA's Strategic Plan can be found at: https://www.drugabuse.gov/about-nida/strategic-plan/goal-3-develop-new-improved-treatments.
In a meeting held by BioCorRx and its development team with NIDA via teleconference on November 8, 2017, NIDA agreed to participate as an observer at the pre-IND meeting for BICX102 with the FDA, which is scheduled for January 24, 2018. BICX102 is the Company's sustained release naltrexone implant being developed for opioid and alcohol use disorders. Brady Granier, CEO of BioCorRx, is also scheduled to meet with NIDA in Washington, DC next week on November 21st for follow up discussions and technical advice on BICX102, as well as to discuss opportunities with BioCorRx's Cognitive Behavioral Therapy (CBT) mobile application recently developed.
Brady Granier, CEO, President, and Director of BioCorRx, commented, "We are honored that NIDA has agreed to engage with us through this process. Our desire is to get this valuable treatment option to market as quickly as possible so that we can help those suffering from opioid use disorder, as well as those suffering from alcohol use disorder. The medical community and government entities have shown strong interest in our products and we have seen a high demand for an antagonist therapy that can last several months. We look forward to the next meeting with NIDA and for their attendance at our upcoming FDA meeting. We believe this naltrexone product can save many more lives if approved and becomes more widely accepted by payers."
About BioCorRx
BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx, Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx, Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
Good day today !
Whatever happening behind the curtains sure is positive !!
BioCorRx Announces Nine Centers to Implement BioCorRx Recovery Program Across Maryland and Virginia
Oct 25, 2017 07:30:00 (ET)
BioCorRx Announces Nine Centers to Implement BioCorRx Recovery Program Across Maryland and Virginia
ANAHEIM, CA--(Marketwired - Oct 25, 2017) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Advanced Spine and Pain (ASAP) will implement the BioCorRx(R) Recovery Program in all nine of its locations in the Maryland and Virginia area. ASAP is the latest group of centers to implement the BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program. The program combines the use of a patient specific naltrexone implant with a proprietary cognitive behavioral therapy (CBT) program specifically tailored for the treatment of alcohol and opioid use disorders, along with one year of peer recovery support and tracking.
Dr. Thomas Raley, Founder of ASAP, commented, "Maryland and Virginia are grossly underserved addiction treatment markets where opioid use disorder continues to rise at an alarming rate. ASAP is happy to offer patients BioCorRx's innovative drug recovery program, a comprehensive, naltrexone-focused medication-assisted treatment (MAT) program for alcohol, heroin, and other opioid addictions. We believe this cutting-edge and highly effective treatment modality has the potential to save many lives from this current epidemic. We plan to offer this program to those individuals who desire to wean off opioids, buprenorphine, alcohol, and heroin."
Brady Granier, CEO, President, and Director of BioCorRx, stated, "We are very pleased that ASAP has chosen to implement the BioCorRx Recovery Program in all nine of its centers. This new partnership increases access points to our program in this affected region. We look forward to working with Dr. Raley and his team. As more centers and groups continue to sign up, we believe we can make a meaningful impact in the lives of people suffering from alcohol and opioid use disorders."
About Advanced Spine and Pain
Advanced Spine and Pain provides a comprehensive multidisciplinary approach to total spine care and pain management in a timely and compassionate manner. ASAP uses the most advanced techniques and validated protocols to assist patients in living without pain and returning to normal daily activities. ASAP provides every patient with the utmost care; giving them the individual attention they need to succeed in the recovery process.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
BioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in Philadelphia
Font size: A | A | A
7:30 AM ET 10/19/17 | Dow Jones
BioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in Philadelphia
ANAHEIM, CA--(Marketwired - Oct 19, 2017) - BioCorRx, Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will have an exhibit at the International Association of Chiefs of Police (IACP) 2017 Annual Conference at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on October 21-24th.
The IACP Annual Conference and Exposition is the leading law enforcement event, bringing more than 14,000 public safety professionals to learn new techniques and advance their knowledge through 200+ workshops in 12 targeted tracks, live demos, hands-on exhibits, new products and networking opportunities.
Brady Granier, CEO, President, and Director of BioCorRx, stated, "We look forward to attending the IACP conference, as law enforcement professionals play a critical role in combating substance abuse within their communities. This conference is a great opportunity to showcase our BioCorRx(R) Recovery Program, which empowers patients to succeed in their overall recovery by utilizing our comprehensive medication-assisted treatment (MAT) program that combines a non-addictive naltrexone implant with proprietary cognitive behavioral therapy (CBT) modules and peer recovery support and tracking. Our collaboration with the City of Anaheim and the Anaheim Police Department has been successful to date and we look forward to offering our program to additional police departments and cities across the U.S."
About BioCorRx
BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx, Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx, Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
(MORE TO FOLLOW) Dow Jones Newswires
October 19, 2017 07:30 ET (11:30 GMT)
BioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol Addiction
Font size: A | A | A
7:00 AM ET 10/17/17 | Dow Jones
BioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol Addiction
ANAHEIM, CA--(Marketwired - Oct 17, 2017) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, President & CEO of BioCorRx, appeared as a guest on MichaeLA hosted by Michaela Pereira live from CNN's Los Angeles bureau, to discuss alcohol addiction and the BioCorRx(R) Recovery Program, which works to help people suffering from alcohol and opioid abuse disorders. The segment can be viewed in the News & Media section of the BioCorRx website. To find out more information on the BioCorRx Recovery Program please visit www.beataddiction.com.
Brady Granier, President & CEO of BioCorRx, stated, "According to an alarming study published in the September 2017 issue of JAMA Psychiatry, one in eight American adults now meet the diagnostic criteria for alcoholism. Further, nearly one in four adults under age 30 meets the diagnostic criteria for alcoholism. Alcohol use disorder (AUD) rose by 49 percent in the first decade of the 2000s, and now affects 12.7 percent of the American population. Our program, the BioCorRx Recovery Program, combines a compounded naltrexone implant per patient prescription with structured, proprietary cognitive behavioral therapy (CBT) modules, as well as peer support. Our company was originally founded primarily for the treatment of alcohol use disorder which is a larger problem, when compared to other substance use disorders, yet doesn't get the attention it deserves. We have seen some very amazing transformations over the years from those participating in our program for AUD. We encourage those families and individuals suffering to give our program a closer look."
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
(MORE TO FOLLOW) Dow Jones Newswires
October 17, 2017 07:00 ET (11:00 GMT)